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Summary 
 
Background:  Clear cell sarcoma (CCSA) is an orphan malignancy, characterised by a 
specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and 
overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine 
kinase inhibitor (TKI) crizotinib in patients with advanced or metastatic CCSA.  
 
Patients and methods: Patients with CCSA received oral crizotinib 250 mg twice daily. 
Primary endpoint was objective response rate (ORR), secondary endpoints included duration 
of response, disease control rate (DCR), progression-free survival (PFS), progression-free rate 
(PFR), overall survival (OS), overall survival rate (OSR) and safety. The study design focused 
on MET+ disease with documented rearrangement of the EWSR1 gene by fluorescence in situ 
hybridization (FISH). 
 
Results: Among 43 consenting patients with the local diagnosis of CCSA, 36 had centrally 
confirmed CCSA, 28 of whom were eligible, treated and evaluable. 26/28 patients had MET+ 
disease, of whom one achieved a confirmed partial response and 17 had stable disease (SD)  
(ORR 3.8%, 95% confidence interval:0.1-19.6). Further efficacy endpoints in MET+ CCSA 
were DCR:69.2% (48.2-85.7%), median PFS:131 days (49-235), median OS:277 days (232-
442). The 3, 6, 12 and 24 month PFR was 53.8% (34.6-73.0), 26.9% (9.8-43.9), 7.7% (1.3-
21.7) and 7.7% (1.3-21.7), respectively. Among two evaluable MET- patients, one had SD 
and one had progression. The most common treatment-related adverse events were nausea 
(18/34[52.9%]), fatigue (17/34[50.0%]), vomiting (12/34[35.3%]), diarrhea (11/34[32.4%]), 
constipation (9/34[26.5%] and blurred vision (7/34[20.6%]).  
 
Conclusions: The PFR with crizotinib in MET+ CCSA is similar to results achieved first-line 
in metastatic soft tissue sarcomas with single-agent doxorubicin. In further lines, the PFS is 
similar to pazopanib in previously treated sarcoma patients.  
 
Clinical trial number: EORTC 90101, EudraCT number 2011-001988-52, NCT01524926 
 
Key words: Clear cell sarcoma, MET gene, EWSR1 gene rearrangement, tyrosine kinase 
inhibitor, crizotinib 
  
Prior presentations  Early data have been reported at the American Society for Clinical 
Oncology Annual Meeting in Chicago (IL) on Sunday, May 31, 2015 (abstract number: 
10547).  
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Key message: 
 
CCSA is a rare chemotherapy-resistant, translocation-related sarcoma. Our phase 2 trial 
demonstrated that crizotinib provided clinical benefit, with 69.2% (18/26, 95% CI:48.2-85.7) 
of CCSA cases with documented EWSR1 gene rearrangement achieving disease control for a 
median of 131 days. We recommend using time-related endpoints for early studies of novel 
agents in STS. 
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Introduction 
 
Clear cell sarcoma (CCSA) is a rare aggressive tumour that primarily affects adolescents and 
young adults, typically involves deep soft tissue of the lower extremities and tends to occur 
near tendons, fascias and aponeuroses.1-5 CCSA is associated with a high rate of local 
recurrence, distant metastasis and lymph node involvement, which is uncommon in other 
types of soft tissue sarcoma (STS).3-5 The five-year OS is around 50-67%, but this decreases 
to 20% in patients with metastatic disease.3,6,7 CCSA tends to be resistant to conventional 
chemotherapy and to radiation therapy.3,6 
 
CCSA is characterised by the t(12;22)(q13;q12) translocation resulting in the Ewing sarcoma 
breakpoint region 1 / activating transcription factor-1 (EWSR1/ATF1) fusion gene, presenting 
in >90% of cases (Supplementary Material/Introduction and Supplementary Figures S1,S2 
provides details on the EWSR1/ATF1 fusion gene and the MET signaling pathway).3,8,9 FISH 
is used to detect these fusions and to establish the diagnosis of CCSA (Supplementary Figure 
S3). Davies et al. confirmed MET expression requires EWS-ATF1 expression, and the 
viability and motility of CCSA is dependent on the HGF/MET axis signaling.3 MET 
inhibition may offer an indirect target for the treatment of CCSA.3 In studies using specific 
inhibitors of MET signalling, MET activity was found to be essential for proliferation and 
survival of CCSA cell lines and xenograft models.3,10,11 
 
Based on MET involvement in CCSA and the absence of a standard treatment for patients 
with advanced disease, strong rationale exists to explore therapies that target the MET 
tyrosine kinase receptor, such as crizotinib (Xalkori®, PF-02341066, Pfizer Inc.).8,11 MET 
engagement results in the activation of multiple downstream signaling pathways, including 
phosphatidylinositol 3 kinase (PI3K)/AKT, RAS/MAPK pathways, etc.3,10,12 While several 
active targets in CCSA exist for future investigations, our study focused on the MET receptor 
as a target for crizotinib inhibition. Crizotinib, a small molecule TKI, inhibits MET, 
anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 receptor tyrosine kinase 
(ROS1).13-17 It interferes with pathways by competitively inhibiting adenosine triphosphate 
from binding to the receptor, thereby preventing phosphorylation.13-17 This blocks the 
downstream cascade of events, inhibiting the growth and survival of MET dependent cells.13-
17 Crizotinib is approved for first-line treatment of patients with metastatic non-small cell lung 
cancer (NSCLC) whose tumours are either ALK- or ROS1-positive, 250 mg twice daily is the 
recommended oral adult dose.18 
 
The European Organization for Research and Treatment of Cancer (EORTC) initiated a 
multinational, multi-tumour, prospective phase 2 clinical trial (EORTC 90101 “CREATE”) to 
evaluate the efficacy and safety of crizotinib in patients with advanced tumours characterized 
by MET and/or ALK alterations. CREATE included ALK or MET driven tumour types in 6 
disease-specific cohorts. We present the independent CCSA cohort results here.  
 
 
Methods 
 
Study design 
 
This was a multicentre, biomarker-driven, single agent, non-randomized, open-label, two-
stage phase 2 trial, assessing the activity and safety of crizotinib in patients with locally 
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advanced or metastatic CCSA (EORTC 90101,ClinicalTrials.gov:NCT01524926). The patient 
population was divided into MET positive (MET+; presence of EWSR1 gene rearrangement) 
and MET negative (MET-; absence of EWSR1 gene rearrangement) sub-cohorts, which were 
analysed separately. Investigators were blinded to the centrally assessed MET status.  
 
Ethics approval was obtained by competent committee(s) and according to national 
legislation. The study was conducted in accordance with: the Declaration of Helsinki; laws 
and regulations of each participating country/institution; and the International Conference on 
Harmonisation-Good Clinical Practice.  
 
Patient enrolment 
  
Patient enrolment was based on a single informed consent per patient but followed a multi-
step procedure. Step 1 prerequisites for registration were a local diagnosis of advanced and/or 
metastatic CCSA deemed incurable by conventional surgery, radiotherapy or systemic 
therapy, the availability of a formalin-fixed paraffin embedded tumour-containing tissue 
block from primary tumour and/or metastatic site, and written informed consent for collection 
of the tissue and all other trial-specific procedures.  
 
The requisite criteria for step 2 included receipt of the tissue block by a central biorepository 
(BioRep, Milan, Italy) with presence of tumour in the shipped material and confirmation of 
the correct diagnosis of CCSA by central pathology. 
 
Screened patients were treated after completion of step 1 and 2, provided all eligibility criteria 
were met. There were no limitations in terms of previous systemic or local treatments for 
CCSA only prior exposure to crizotinib or other specific MET-inhibiting agents was not 
allowed. Details on the patient selection are described in the study protocol 
(http://www.eortc.be/services/doc/protocols/90101v10.0.pdf). 
 
Treatment, safety and efficacy assessment 
 
Eligible patients with centrally confirmed diagnosis of CCSA were treated with oral crizotinib 
at a starting dose of 250 mg twice daily. One treatment cycle was defined as 21 days in 
duration. Treatment continued until progression, unacceptable toxicity, or patient refusal. 
Dosing instructions were in line with the standard use of crizotinib in the labelled NSCLC 
indication. Dose and schedule modifications were defined in the protocol.  
 
Safety information was collected at baseline, day 15 of cycle 1 and 2, and at the end of every 
cycle applying the Common Terminology Criteria for Adverse Events [CTCAE] version 4.0. 
Tumour assessments were performed every other cycle by the local investigator according to 
RECIST 1.1 on the basis of computer tomography or magnetic resonance imaging. Digital 
images were collected and objective responses were centrally reviewed. 
 
Assessment of MET alterations 
 
Patients were attributed to the MET+ sub-cohort based on the presence of the EWSR1 gene 
rearrangement. This was assessed by FISH with the commercially available dual colour 
break-apart rearrangement probe Vysis® LSI® EWSR1(22q12)(Abbott Molecular). At least 
15% of tumour cells had to show a rearrangement for a case to be considered MET+.  This 
threshold was established by validation of the specific FISH probe in the specific indication in 
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the laboratory performing the evaluation, as well as running this test in clinical routine. 
EWSR1 rearrangement is a molecular hallmark of CCSA, so a very low rate of MET- cases 
were expected. 
 
Outcomes 
 
The main objective was to study the activity of crizotinib in MET+ CCSA patients. The 
primary endpoint was ORR per RECIST 1.1 with response confirmation, assessed by the local 
investigator. This endpoint was chosen based on the response pattern seen with crizotinib in 
the labelled indication of NSCLC and in the absence of reliable reference data on PFS or PFR 
in CCSA. Secondary endpoints included: duration of response, DCR, PFS, PFR, OS, OSR, 
safety, and correlative/translational research endpoints. The DCR was defined as the 
percentage of patients achieving either a complete (CR) or partial response (PR) or SD. 
 
Statistical analysis 
 
The statistical design was conceptually focused on centrally documented EWSR1 fusion 
(MET+ sub-cohort) cases. It was decided that showing an ORR > 10% (null hypothesis) in 
CCSA MET+ patients, a rare population, resistant to chemotherapy and radiotherapy, would 
be promising for future research. Therefore a Simon's optimal two-stage design19 was 
implemented with the aim of excluding an ORR ≤10% under the alternative assumption that 
30% ORR can be achieved with crizotinib. The type I error and power were set at 10%. In 
stage 1, if at least two out of the first 12 eligible and evaluable CCSA MET+ patients 
achieved a confirmed RECIST PR or CR, a maximum of 35 patients were to be enrolled. In 
stage 2, if less than 6 out of 35 eligible and evaluable patients responded, the treatment was 
declared ineffective. If at least 6 out of the 35 patients responded, further study of crizotinib in 
CCSA was warranted.  
 
MET- patients served as a non-randomized, non-historical, treated internal control. The entry 
of “all comers” independent of their MET status was allowed, to avoid delay of treatment for 
patients in need of an active intervention and to provide reference data for both subsets. The 
entry of MET- cases was considered ethical due to the lack of validated treatment alternatives 
for this disease. 
 
The stopping rules and activity endpoints details are provided in Supplementary 
Material/Methodology. Analyses were performed using SAS version9.4(SAS 
Institute,Cary,United States).  
 
 
Results 
 
Patient disposition, reference pathology, clinical screening and enrolment 
 
Between January 28, 2013 and December 1, 2014, 16 sites in 8 European countries recruited 
43 patients with local diagnosis of CCSA. Only 36/43(84%) patients had a confirmed CCSA 
according to reference pathology; were eligible for screening and potential treatment.  
 
The 7 non-confirmed, non-eligible cases included two cases of melanoma, three non-specified 
malignancies, and one case with insufficient material for reference pathology. One patient 
withdrew from study before central review. These patients were not treated.  
8 
 
A total of 34 of the 36 patients with centrally confirmed CCSA were enrolled in the study 
(step 3) and started treatment with crizotinib. The two remaining patients withdrew consent. 
A total of 28 eligible patients (26 MET+ and 2 MET-) with confirmed CCSA who started 
treatment with crizotinib were evaluable for the primary endpoint (Supplementary Figure S4 
provides the CONSORT-like patient disposition).  
 
As expected, the number of patients with MET- disease was very low (two patients eligible 
and evaluable). As the trial was conceptually focused on EWSR1 rearranged cases, and due to 
the low sample size of MET- disease, only some key results obtained in the latter cases will be 
presented. Supplementary Figure S4 depicts the trial profile.   
 
Genetic analysis and molecular epidemiology 
 
FISH testing was completed according to protocol by the academic laboratory within a 
median time of 4 days (range:1-15) after receipt of technically useful, unstained slides from 
the central biorepository.  
 
Among 36 patients with centrally confirmed CCSA diagnosis, 32(88.9%) had documented 
EWSR1 rearrangement (MET+ cases). Only 3 patients (8.3 %) had no detectable EWSR1. 
FISH testing could not be performed in the remaining patient due to technical failure. 
Supplementary Table S1 shows an overview of the molecular characteristics.  
 
Due to rapid accrual of patients, a delay in reporting clinical efficacy results to EORTC, and 
in the light of the lack of treatment alternatives for this highly resistant malignancy, we 
overrecruited the CCSA cohort of EORTC 90101. We recruited more than the 12 MET+ 
CCSA patients required to complete stage 1, but less than 35 eligible and evaluable patients 
for completing stage 2 according to protocol. Recruitment to both the MET+ and MET- CCSA 
sub-cohorts was suspended on February 5, 2015, after having analyzed the ORR in the first 12 
eligible and evaluable MET+ cases. 
 
Patient characteristics 
 
Among the total group with confirmed diagnosis of CCSA, 31 patients with MET+ disease 
were treated, two patients with MET- CCSA entered the treatment phase and one patient with 
MET? received crizotinib. 
 
Table.1A shows the characteristics of these 34 treated patients. Their median age was 44 
years, 35.3%(12/34) had an ECOG PS of 1 and the majority (91.2%[31/34]) had undergone 
prior surgery. Only 26.5%(9/34) had received prior systemic therapy, illustrating the lack of 
treatment options outside of clinical trials for such patients. 
 
Crizotinib treatment  
 
As of March 2 2017, with a median follow-up of 281 days (range:43-933), 2.9 %(1/34) of 
patients were still receiving treatment. Only 38.2%(13/34) of treated patients required dose 
reductions or dose modifications (Table.1B). The total treatment duration with crizotinib 
ranged from 3 to 849+ days.  Reasons for treatment discontinuation are shown in table.1B.   
 
Activity of crizotinib in MET+ CCSA 
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The primary endpoint was the ORR as assessed by the local investigator, with response 
confirmation. An objective PR was observed in 1/26 MET+ patients (3.8% ORR;95% 
confidence interval [CI]:0.1-19.6%). The primary endpoint of the trial was not met. The 
duration of response in the responding patient was 851+ days; the patient is still on active 
treatment at the data cut-off, having received 40+ cycles of treatment. RECIST SD was 
observed in 17/26 MET+ patients (65.4%). Disease progression was seen in 8 patients 
(30.8%). Disease control was achieved in 18/26 MET+ patients (DCR;69.2%,95% CI:48.2-
85.7). The median PFS was 131 days (95% CI:49-235; (Supplementary Figure S5). The 3, 6, 
12 and 24 month PFR was 53.8%(34.6-73.0), 26.9%(9.8-43.9), 7.7%(1.3-21.7) and 7.7%(1.3-
21.7), respectively. The median OS was 277 days (95% CI:232-442), and the OSR was 
36.1%(95% CI:18.2-54.3%) at 1 year and 9.4%(95% CI:1.7-25.3%) at 2 years 
(Supplementary Figure S6). Figure.1A illustrates the maximum shrinkage of target lesions 
during treatment. Half of the MET+ CCSA cases had crizotinib measurable reduction of 
target lesions. Figure.1B summarizes the clinical course of all treated patients. 
 
Activity of crizotinib in MET-/MET? CCSA 
 
None of the MET- patients had a response: one had SD followed PD at day 143 and one had 
PD at day 66. Key efficacy data for the total study population are summarized in table.1C.  
 
Safety and toxicity 
 
No new or unexpected safety signals were detected. The most common treatment-related 
adverse events occurring in ≥10% of the 34 patients who started crizotinib were nausea 
(52.9% of patients), fatigue (50.0%), vomiting (35.3%), diarrhoea (32.4%), constipation 
(26.5%), and blurred vision (20. 6%). The reported treatment-related grade 3/4 adverse events 
were nausea (two patients), fatigue (two), gastritis (one), Qt prolongation (one) and anorexia 
(one). Supplementary Tables S2 and S3 show adverse events occurring in ≥10% of treated 
patients. 
 
Three deaths occurred on treatment or within 4 weeks of treatment-discontinuation, all 
deemed unrelated to crizotinib treatment. There was one possibly treatment-related death. 
This patient developed pneumonia, pulmonary embolism and pneumonitis during cycle 12 of 
treatment. 
 
 
Discussion   
 
The treatment of advanced, inoperable CCSA remains a challenge due to the lack of an 
established systemic treatment standard. Information from prospective clinical trials on the 
efficacy of systemic treatments for CCSA is limited. EORTC 90101 CREATE is likely the 
first, well powered study in this setting. The main objective of this phase 2 study was to 
assess the activity of crizotinib in this rare and chemotherapy-resistant, translocation-related 
sarcoma. The ORR was 3.8%(1/26 PR,95% CI:0.1-19.6%) and the primary endpoint of the 
trial was not met, as we did not observe at least two objective and radiologically confirmed 
responses among the first 12 eligible and evaluable MET+ cases. 
 
Multiple factors led to overrecruitment of patients beyond stage 1 of Simon’s optimal two-
stage design. We saw rapid accrual of CCSA cases, with the majority of patients previously 
10 
untreated, reflecting the high unmet medical need in this orphan malignancy. Investigators 
observed a large proportion of patients achieving early SD under treatment with crizotinib, 
and all these cases could theoretically still convert upon further exposure to an objective 
response. Furthermore, all responses had to be confirmed by a second scan, to be in line with 
RECIST 1.1. This led to a delay in reporting efficacy data to EORTC, as investigators had to 
wait until their patients came off study or had reached a confirmed PR. By that time we had 
exceeded the minimum sample size to assess the futility of crizotinib, without having reached 
the stage 2 sample size according to trial design. Due to the lack of treatment alternatives we 
accepted this overrecruitment and this also provided an opportunity to gain deeper insight into 
the natural course of this cancer. 
 
Even though we found alterations leading to MET expression in 88.9% of our cases, which is 
in line with the literature, the inhibition of MET by crizotinib only translated in one, however 
durable response. It is unclear why this patient had such exceptional response, but we hope 
that further tissue-based analysis will provide an explanation. We cannot exclude that this 
response was induced by effects other than MET inhibition, as crizotinib inhibits more than 
one target. Interestingly, 18/26(69.2%,95% CI:48.2-85.7) of our cases achieved disease 
control for a median of 131 days. This suggests that PFS or PFR would have been better 
endpoints for assessing the efficacy of crizotinib in this disease. The response pattern of 
MET-driven malignancies to TKI might be different from the volumetric responses seen in 
ALK-driven NSCLC. 
 
Although it was shown that the presence of EWSR1-ATF1 fusion protein, characteristic of 
CCSA, was required for MET expression and that MET inhibition significantly reduced 
CCSA cell growth in vitro3 it is not yet known if MET expression and/or activation is present 
at the same level in all CCSA cases. It is possible that other factors (e.g. level of HGF 
expression) contributes to the role of MET in oncogenesis and therefore variable elements 
may influence the response to MET inhibitors. This hypothesis, along with the influence of 
MET-related pathways status, is currently being tested. 
 
Based on a retrospective statistical analysis of multiple EORTC sarcoma trials, Van Glabbeke 
et al.2 proposed reference values for potentially active agents in STS. For first-line therapy, 
she recommended a 6 month PFR of >30-56% and for second-line therapy a 3 month PFR of 
>40% as an indicator of promising activity, while a 6 month PFR of <20% would suggest 
inactivity. In our CCSA MET+ group, the 3 and 6 month PFR was 53.8%(34.6-73.0) and 
26.9%(9.8-43.9). In an exploratory analysis we looked at the outcome achieved with 
crizotinib in pretreated (N=7/26) versus non-pretreated (N=19/26) patients with EWSR1 
rearrangement. The first-line subset had a 3 and 6 month PFR of 52.6 %(30.2-75.1) and 
42.1%(19.9-64.3%). The second-line subset had a 3 and 6 month PFR of 57.1%(20.5-93.8%) 
and 14.3%(0.0-40.2%). This post hoc analysis suggests that crizotinib is active in this setting, 
following Van Glabbeke’s criteria. 
 
The approval and routine use of most drugs for the treatment of STS has been based on trials 
pooling various types of sarcoma together, which limits the interpretation of the efficacy of 
such agents in a given histological subtype. Our phase 2 trial was highly histotype-specific, 
involved reference pathology and genetic characterization of CCSA as one of the rarest and 
most treatment-resistant members of the STS family. In this context it is noteworthy that the 
PFS seen with crizotinib in MET+ CCSA was similar to results achieved in non-selected 
patients with advanced STS treated with single-agent doxorubicin in first line (4.6 months, 
95% CI:2.9-5.6),20 or with the oral angiogenesis inhibitor pazopanib in previously treated 
11 
patients (4.6 months, 95% CI:3.7-4.8).2 In our smaller, more exploratory study, crizotinib 
achieved a median PFS in CCSA with MET alterations of 4.4 months (95% CI:1.6-7.8). 
  
Statistically we focused on cases with EWSR1 positive CCSA as assessed by FISH, while 
allowing “all comers” to enter the study, provided they had a centrally confirmed diagnosis. 
This served multiple strategic purposes: to avoid delay during study entry after consent; to 
give the laboratory sufficient time for FISH testing; to offer an experimental treatment to 
patients with an unmet medical need; to collect data on the molecular epidemiology of 
advanced CCSA; and to provide a reference for future trials in this rare cancer. The expected 
small sample size of the MET- subcohort of our trial population however precludes drawing 
definitive conclusions for this group. 
 
Reference pathology was an important component of the trial. Our pathology review was 
completed within a median of 3 days (range,1-17) after receipt of unstained slides. It was 
based on a review of local pathology and FISH reports, central microscopy and additional 
stainings if required, and FISH testing in Leuven in all cases. Of note, only 36 of the 43 
consenting patients had a centrally confirmed CCSA. This highlights once again the 
complexity of proper morphological characterization of rare malignancies, even in highly 
dedicated academic institutions, especially in tumour types that can mimick other diseases. 
The misclassification rate here was similar to that seen in other STS studies. 
 
Another specific feature was the mandatory collection of a non-returnable, archived tissue 
block from all participating patients for research. Many investigators are hesitant to provide 
commercial trial sponsors with a tissue block for research, while EORTC as an academic non-
for-profit organization has the capacity to function as a biobank and non-commercial 
facilitator of translational work. We were able to collect tissue from 42 consenting patients, 
including material from 36 individuals with centrally confirmed CCSA. This precious 
resource is now the basis for multiple ongoing and planned exploratory studies, which will 
lead to a better understanding of the CCSA biology and the identification of prognostic or 
predictive biomarkers and treatment strategies for this rare cancer. 
 
Our study showed variable response in the MET+ cohort which suggests the presence of other 
factors in combination with EWSR1 rearrangement which might predict crizotinib’s efficacy. 
We are currently performing correlative studies using whole exome sequencing to evaluate 
the mutational profile and low-coverage whole genome sequencing to study copy number 
changes, which will be supplemented by research using tissue microarrays constructed from 
the tissue blocks, to better understand the molecular background of CCSA and individual 
cases’ sensitivity or resistance to crizotinib.  
 
In our complex trial we demonstrated that EORTC can perform multi-tumour, precision-
medicine phase 2 trials in rare cancers with collection of tissue blocks, real time reference 
pathology and molecular characterization. Given the inherent limitations of performing larger 
prospective trials in ultra-rare diseases, innovative trial methodology like the basket approach 
chosen in EORTC 90101, and new regulatory mechanisms are required to provide patients 
with orphan malignancies with potentially active drugs such as crizotinib. 
 
The adverse events observed in this study were consistent with safety data for crizotinib in 
patients with NSCLC. No new adverse events were observed. Dose intensity was high and the 
incidence of dose modifications was relatively low. 
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This study illustrates once again the methodological limitations using response rate in early 
clinical trials in oncology. This endpoint had been chosen based on the impressive volumetric 
responses seen with crizotinib in the labelled indication of ALK+ NSCLC and due to the 
absence of reliable reference data on PFS or PFR in this rare type of sarcoma. In general, 
EORTC is recommending using time-related endpoints such as PFR during the early 
exploration of novel agents in STS,1 which provided the phase 2 rationale for at least two 
successful registration trials during the past 5 years.2,21 
  
We were able to demonstrate that crizotinib provided clinical benefit to patients with locally 
advanced or metastatic MET+ CCSA. This is noteworthy as this orphan malignancy is 
renowned for being profoundly resistant to conventional systemic agents. Response rate 
should not be the primary endpoint for future phase 2 trials with MET inhibiting agents for 
CCSA. DCR, PFS and/or PFR would be a more appropriate reflection of the therapeutic 
effects of treatments in this disease, where progression arrest might be more important than 
shrinkage of the tumour and its metastasis. Other MET inhibitors, such as small molecules 
(highly specific or multi-targeted) or monoclonal antibodes, either given as single agents or in 
combination with other drugs, could be studied in future CCSA trials.  
13 
Other local investigators  
 
Germany: Prof B. Kasper, MD  
 
 
Acknowledgements 
 
CREATE was sponsored by EORTC and supported by Pfizer. We thank the involved patients 
and their families for participating in this study. We thank the EORTC Headquarters team, 
investigators, nurses, and other study staff for their contributions to this trial. P. Schöffski 
funded editorial support, and J. O’Regan (Bingham Mayne and Smith Ltd.) provided editorial 
assistance with an early draft of the manuscript. This publication was supported by the 
EORTC Cancer Research Fund. T. van Cann and J. Cornillie helped with the review of 
radiology. S. Strauss is supported by the NIHR, University College London Hospitals 
Biomedical Research Centre. M. Lia received a fellowship supported by Fonds Cancer 
(Brussels, Belgium). We also want to thank the members of Steering Committee for their 
contribution. 
 
 
Funding 
 
This work was supported by EORTC and supported by Pfizer Inc. as an investigator-initiated 
trial (no grant number is applicable). EORTC was the legal sponsor. Pfizer Inc. provided the 
investigational agent and funding, but had no role in the study design, data collection, 
analysis, interpretation, writing of the report, or decision to publish this report. The database 
is held by EORTC, and EORTC statisticians performed the analysis. 
 
 
Disclosure 
 
PS: no competing interest 
AW: no competing interest 
PRutkowski: received honoraria from Pfizer outside the scope of this study  
JYB: Research support and honoraria from Pfizer outside the scope of this study 
LHL: received honoraria from Pfizer outside the scope of this study 
SS: no competing interest 
AA: no competing interest  
FD: no competing interest 
SR: no competing interest 
VG: received honoraria from Bristol Myers Squibb, Novartis, Pfizer; advisory board for 
Bristol Myers Squibb, Novartis, Pfizer, Roche; received travel grant from Bristol Myers 
Squibb, MSD, Novartis, Pfizer  
MGL: no competing interest 
PReichardt: received grants and personal fees from Novartis, received personal fees from 
Pfizer, Bayer, PharmaMar, Amgen, AstraZeneca, Clinigen, Lilly, Deciphera, outside the 
submitted work  
JS: Honoraria from Roche, Novartis, Swedish Orphan, Merck  
WvdG: Research support from Novartis, honoraria from Bayer 
RS: no competing interest 
MDR: no competing interest 
14 
SM: no competing interest 
ML: no competing interest 
TR: no competing interest 
LC: no competing interest 
SB: received honoraria from Pfizer for consulting and CME activities  
 
 
  
15 
 
References 
 
 
1. Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma 
Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue 
sarcomas.Eur J Cancer.2002;38:543-549 
 
2. van der Graaf WT1, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma 
(PALETTE): a randomised, double-blind, placebo-controlled phase 3 
trial.Lancet.2012;379:1879-1886 
 
3. Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and 
its ligand, Hepatocyte Growth Factor, as therapeutic targets in clear cell. Sarcoma.Cancer 
Res.2010;70:639–645. 
 
4. Wang WL, Mayordomo E, Zhang W, et al. Detection and characterization of EWSR1/ATF1 and 
EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts).Mod 
Pathol.2009;22:1201-1209. 
 
5. Hocar O, Le Cesne A, Berissi S, et al. Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A 
Clinicopathologic Study of 52 Cases.Dermatology Research and Practice 2012: 
984096.doi:10.1155/2012/984096. 
 
6. Speleman R and Sciot F. Clear cell sarcoma of soft tissue. In World Health Organization 
Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone, ed. C 
Fletcher, K Unni, F Mertens.IARC Press,Lyon,France,2002,pp.211-212. 
 
7. Hisaoka M, Ishida T, Kuo TT,et al. Clear cell sarcoma of soft tissue: a clinicopathologic, 
immunohistochemical, and molecular analysis of 33 cases.Am J Surg Pathol.2008;32:452-460. 
 
8. Schaefer KL, Brachwitz K, Wai DH, et al. Expression profiling of t(12;22) positive clear cell 
sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes 
including ERBB3.Cancer Res.2004;64:3395-3405. 
 
9. Wang W-L, Mayordomo E, Zhang W, et al. Detection and characterization of EWSR1/ATF1 and 
EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts).Modern 
Pathology.2009;22:1201–1209 
 
10. McGill GG, Haq R, Nishimura EK, Fisher DE. c-Met expression is regulated by Mitf in the 
melanocyte lineage.J Biol Chem.2006;281:10365-10373 
 
11. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of 
MET, in patients with microphthalmia transcription factor-associated tumors: results of a 
multicenter phase 2 trial.Cancer.2012;118:5894-5902. 
 
12. Meyer R, D'Alessandro LA, Kar S, et al. Heterogeneous kinetics of AKT signaling in individual 
cells are accounted for by variable protein concentration.Front Physiol.2012;3:451. 
 
16 
13. Rodig SJ, Shapiro GI. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor 
tyrosine kinases.Curr Opin Investig Drugs.2010;11:1477-1490. 
 
14. Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: A comprehensive review.South 
Asian J Cancer.2013;2:91-97. 
 
15. Karachaliou N, Rosel R, Molina MA, Viteri S. Predicting resistance by selection of signaling 
pathways.Transl Lung Cancer Res.2014;3:107-115 
 
16. Stone A, Harrington K, Frakes M, Blank K, Rajanna S. EGFR and c-Met Inhibitors are Effective 
in Reducing Tumorigenicity in Cancer.J Carcinog Mutagen.2014;5:173.doi:10.4172/2157-
2518.1000173 
 
17. Camidge DR, Ou S-HI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with 
advanced c-MET-amplified non-small cell lung cancer (NSCLC).2014 ASCO Annual Meeting.J 
Clin Oncol.32:5s,2014(suppl;abstr 8001) 
 
18. Crizotinib Summary of Product Characteristics (SPC). Available at:  
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/002489/WC500134759.pdf (Last accessed 2 March 2015). 
 
19. Simon R. Optimal two-stage designs for phase II clinical trials.Controlled Clinical 
Trials.1989;10:1–10 
 
20. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus 
ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised 
controlled phase 3 trial.Lancet Oncol.2014;15:415-23 
 
21. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients 
with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 
trial.Lancet.2016;387:1629-37 
 
  
17 
Figure.1A. Maximum shrinkage of target lesions (per protocol) according to local 
investigator’s assessment. 
 
 
Figure.1B. Clinical course of patients in the CCSA MET+ and MET- sub-cohorts. 
 
